Our results revealed a novel cardiac hypertrophic regulating model composed of FOXO3a, PARKIN and mitophagy, which may lead to future studies to explore not only the implications of this model in hypertrophy, but also the application as potential therapeutic targets and strategies for cardiac hypertrophy and heart failure. This evidence concerns the gene PRKN and cardiac hypertrophy.